Leaders in Pharmaceutical Business Intelligence (LPBI) Group

LIVE Remarks by Rachel Kaprielian, Tony Chat and Mike Huckman @ 2016 MassBio Annual Meeting 04/01/2016 12:45 PM Royal Sonesta Hotel, Cambridge, MA

Reporter: Aviva Lev-Ari, PhD, RN

• Rachel Kaprielian, Region Director, US Health & Human Services

1. WELLNESS vs sickness
2. Innovations
3. MediCare – $1Billion a day paid by MediCare for services Nationwide
4. EMR  – 3 out of 4 hospitals are using it, compliance
5. Diabetes and Mental Health — if improved, cost of Healthcare will go down
6. Rural areas in ME
7. moonshot, 600,000 will die of Cancer
8. AIDS – chronic managed condition
9. Federal help contextualize
10. Affordable Care is about ACCESS
11. Value-based payments – information, data, delivery
12. New England, ME is the weakest in subscription 89%, MA – 98% coverage 99% Children

• Tony Coles, CEO, Yumanity Therapeutics, ALC,Parkinsons, Alheimsers’ Disease

1. Trends, Cost of real estate for BioLabs, 20% of budget goes to RE
2. 1992 at Merck, ACE drug, controlling cost and hospitalization
3. Cost, value based pricing, improvement in mortality vs systmes savings. Rebates go up, profits go up
4. pay for performance
5. Impact on Insurance industry
6. Merck taught  excellence:
7. BMQ – intense fierce competitiveness
8. Merck recognis=zed that time is changing thus, self-regulate, aplication of Precision Medicine
9. Pharma has superior return to shareholder in parallel to innovations and superior products
10. Goals : Moonshot is Chapter two of Chapter one – 1960s the start of Cancer research
11. Bi-Partisan support for moonshot initiative, 1 Million cohort recruitment needs more than $17 Million
12. Greatest industry why be defensive?
13. I think the next President: IF D – Centrist Agenda, if R – On Innovations

• Mike Huckman, Chief Communications Specialist, Pure Communications, Interviewer

1. Big Pharma Executive move to Biotech
2. cost of medicine – survey 35,000 interviewed  – 30%  care giver  1 in 5 cut back on their own healthcare. Burden on care givers
3. What is Profit margins for Life Sciences pursuits? CAp on returns and on Shareholders value
4. Fix problems of HealthCare – what would this problem be